Special Survey for Paediatric Subjects

Novo Nordisk A/S241 enrolled

Overview

This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using NovoRapid® (insulin aspart) in children with type 1 and type 2 diabetes under normal clinical practice conditions.

Study Type

OBSERVATIONAL

Enrollment

241

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

insulin aspartDRUG

Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice

Eligibility

Sex: ALLMax age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Requiring insulin therapy * No treatment history of NovoRapid® (insulin aspart)

Locations (1)

Unnamed facility

Tokyo, Japan

Outcomes

Primary Outcomes

Hypoglycaemic events

Secondary Outcomes

HbA1c (glycosylated haemoglobin)

Physicial examination

Adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.